Andrew J. Armstrong, MD, MSc | Authors

Duke Health

Articles

Safety Profile of LuPSMA Therapy in mCRPC

July 07, 2021

Dr Andrew J. Armstrong reviews the safety of LuPSMA therapy as compared to cabazitaxel as seen in the phase 2 TheraP trial and comments on sequencing strategies for patients with metastatic castration-resistant prostate cancer.

Response to LuPSMA Therapy in mCRPC

June 30, 2021

Andrew J. Armstrong, MD, MSc, discusses the survival benefit of LuPSMA therapy in patients with metastatic castration-resistant prostate cancer and evaluates the response to therapy compared with other agents.

Standard of Care for PSMA-Positive mCRPC

June 30, 2021

Andrew J. Armstrong, MD, MSc, provides insight on unmet needs and the use of androgen receptor inhibitors for patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.